Carl G Maki Selected Research

nutlin 3

1/2019	The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
1/2018	p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
1/2018	DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.
5/2016	Modeling the Etiology of p53-mutated Cancer Cells.
1/2014	Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
1/2011	Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
12/2010	p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
7/2010	Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.
4/2010	Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.
10/2008	Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl G Maki Research Topics

Disease

17	Neoplasms (Cancer) 12/2022 - 10/2008
5	Breast Neoplasms (Breast Cancer) 05/2022 - 08/2014
4	Tetraploidy 01/2014 - 10/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2022 - 01/2019
3	Triple Negative Breast Neoplasms 05/2022 - 11/2020
3	Osteosarcoma (Osteogenic Sarcoma) 11/2017 - 01/2014
2	Colonic Neoplasms (Colon Cancer) 01/2018 - 01/2014
2	Leukemia 05/2009 - 12/2003
1	Hypoxia (Hypoxemia) 05/2022
1	Carcinoma (Carcinomatosis) 11/2020
1	Colorectal Neoplasms (Colorectal Cancer) 05/2016
1	Aneuploidy (Aneuploid) 01/2014

Drug/Important Bio-Agent (IBA)

10	nutlin 3IBA 01/2019 - 10/2008
8	Cisplatin (Platino)FDA LinkGeneric 12/2022 - 10/2008
3	Estrogen ReceptorsIBA 05/2022 - 10/2014
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 05/2009
2	Histone DemethylasesIBA 12/2022 - 01/2019
2	4-hydroxy-N-desmethyltamoxifenIBA 01/2022 - 11/2021
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 11/2021
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2021
2	Tamoxifen FDA LinkGeneric 11/2021 - 10/2014
2	PlatinumIBA 01/2019 - 01/2013
2	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2022
1	4,17 beta-dihydroxy-4-androstene-3-oneIBA 05/2022
1	EnzymesIBA 05/2022
1	Estrogens (Estrogen)FDA Link 05/2022
1	afimoxifene (hydroxytamoxifen)IBA 05/2022
1	CarboxypeptidasesIBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	Aurora Kinase AIBA 01/2022
1	Y 29794IBA 11/2020
1	Prolyl OligopeptidasesIBA 11/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2019
1	3-deazaneplanocinIBA 01/2018
1	Insulin (Novolin)FDA Link 05/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 05/2016
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2014
1	lysosomal Pro-X carboxypeptidaseIBA 08/2014
1	Messenger RNA (mRNA)IBA 01/2014
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2014
1	Small Interfering RNA (siRNA)IBA 01/2013
1	Pharmaceutical PreparationsIBA 01/2013
1	Cyclin BIBA 01/2013
1	Cyclin AIBA 01/2013
1	7-hydroxystaurosporine (UCN 01)IBA 01/2013
1	Telomere-Binding ProteinsIBA 12/2010
1	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2010
1	DNA (Deoxyribonucleic Acid)IBA 10/2008
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2003
1	Multiprotein ComplexesIBA 12/2003

Therapy/Procedure

10	Therapeutics 12/2022 - 10/2008
3	Drug Therapy (Chemotherapy) 01/2019 - 01/2014